ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer.

[1]  S. Balk,et al.  WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. , 2023, Cancer research.

[2]  P. Lopez-Bergami.  ROR2, a driver of “phenotype switching” in melanoma? , 2022, Cancer Cell International.

[3]  Tao Wang,et al.  Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance , 2022, Nature Cancer.

[4]  L. Mazutis,et al.  Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling , 2022, Science.

[5]  A. Yu,et al.  Bioengineered BERA-Wnt5a siRNA targeting Wnt5a/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment. , 2022, Molecular cancer therapeutics.

[6]  Wen-Hui Lien,et al.  ROR2 regulates self-renewal and maintenance of hair follicle stem cells , 2022, Nature Communications.

[7]  A. Zoubeidi,et al.  ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer , 2022, Nature Communications.

[8]  P. Lopez-Bergami,et al.  Cellular and Molecular Mechanisms Implicated in the Dual Role of ROR2 in Cancer. , 2022, Critical reviews in oncology/hematology.

[9]  H. G. van der Poel,et al.  Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence , 2021, medRxiv.

[10]  H. G. van der Poel,et al.  An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer , 2021, Nature Cell Biology.

[11]  Jie Wang,et al.  Non-apoptotic function of caspase-8 confers prostate cancer enzalutamide resistance via NF-κB activation , 2021, Cell Death & Disease.

[12]  V. Quaranta,et al.  ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer , 2021, Genes & development.

[13]  Liewei Wang,et al.  A noncanonical AR addiction drives enzalutamide resistance in prostate cancer , 2021, Nature Communications.

[14]  A. Bleckmann,et al.  The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention , 2021, Cells.

[15]  A. Gao,et al.  WLS-Wnt signaling promotes neuroendocrine prostate cancer , 2021, iScience.

[16]  M. Rubin,et al.  Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers. , 2020, Molecular cell.

[17]  Oh-Joon Kwon,et al.  Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1+ prostate luminal cells , 2020, Oncogene.

[18]  Wen-en Zhao,et al.  Current development of CBP/p300 inhibitors in the last decade. , 2020, European journal of medicinal chemistry.

[19]  P. Lopez-Bergami,et al.  The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment , 2020, Cancer and Metastasis Reviews.

[20]  Haiyong Peng,et al.  Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications , 2020, The Journal of Biological Chemistry.

[21]  M. Rubin,et al.  Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity , 2020, Nature Communications.

[22]  F. D. de Sauvage,et al.  The great escape: tumour cell plasticity in resistance to targeted therapy , 2019, Nature Reviews Drug Discovery.

[23]  P. Nelson,et al.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.

[24]  G. Patel,et al.  Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play , 2019, Cancers.

[25]  M. Loda,et al.  The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance , 2019, Clinical Cancer Research.

[26]  A. Villers,et al.  ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Biswal,et al.  Cell signaling and cancer: a mechanistic insight into drug resistance , 2019, Molecular Biology Reports.

[28]  L. Mei,et al.  Agrin-Lrp4-Ror2 signaling regulates adult hippocampal neurogenesis in mice , 2019, eLife.

[29]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[30]  N. Agarwal,et al.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. , 2019, The New England journal of medicine.

[31]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[32]  R. Kageyama,et al.  High Hes1 expression and resultant Ascl1 suppression regulate quiescent vs. active neural stem cells in the adult mouse brain , 2019, Genes & development.

[33]  Steven L. Chang,et al.  Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Libing Song,et al.  Wnt5a induces and maintains prostate cancer cells dormancy in bone , 2018, The Journal of experimental medicine.

[35]  A. Falini,et al.  The proneural gene ASCL1 governs the transcriptional subgroup affiliation in glioblastoma stem cells by directly repressing the mesenchymal gene NDRG1 , 2018, Cell Death & Differentiation.

[36]  Xiaoyan Zhang,et al.  Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis , 2018, Nucleic Acids Res..

[37]  R. Beerli,et al.  Novel Antibody Drug Conjugates Targeting Tumor-Associated Receptor Tyrosine Kinase ROR2 by Functional Screening of Fully Human Antibody Libraries Using Transpo-mAb Display on Progenitor B Cells , 2018, Front. Immunol..

[38]  M. Ohba,et al.  Receptor Tyrosine Kinase-Targeted Cancer Therapy , 2018, International journal of molecular sciences.

[39]  Zheng Wang,et al.  Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers , 2018, Nature Communications.

[40]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  F. Saad,et al.  Enzalutamide in Men with Nonmetastatic, Castration‐Resistant Prostate Cancer , 2018, The New England journal of medicine.

[42]  M. Rubin,et al.  Patient derived organoids to model rare prostate cancer phenotypes , 2018, Nature Communications.

[43]  G. Hampton,et al.  A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types , 2018, npj Precision Oncology.

[44]  A. Zoubeidi,et al.  Cellular plasticity and the neuroendocrine phenotype in prostate cancer , 2018, Nature Reviews Urology.

[45]  Y. Minami,et al.  Diverse roles for the ror‐family receptor tyrosine kinases in neurons and glial cells during development and repair of the nervous system , 2018, Developmental dynamics : an official publication of the American Association of Anatomists.

[46]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[47]  Gary D Bader,et al.  ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells. , 2017, Cell stem cell.

[48]  M. Rubin,et al.  Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer. , 2017, Cancer discovery.

[49]  V. Njar,et al.  Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  Ximing J. Yang,et al.  FOXA1 inhibits prostate cancer neuroendocrine differentiation , 2017, Oncogene.

[51]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[52]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[53]  A. Aiba,et al.  Critical role of Ror2 receptor tyrosine kinase in regulating cell cycle progression of reactive astrocytes following brain injury , 2017, Glia.

[54]  Tao Liu,et al.  Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse , 2016, Nucleic Acids Res..

[55]  Hedi Peterson,et al.  g:Profiler—a web server for functional interpretation of gene lists (2016 update) , 2016, Nucleic Acids Res..

[56]  Fidel Ramírez,et al.  deepTools2: a next generation web server for deep-sequencing data analysis , 2016, Nucleic Acids Res..

[57]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[58]  Sridhar Ramaswamy,et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.

[59]  Y. Ohe,et al.  Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinoma , 2015, Journal of Cancer Research and Clinical Oncology.

[60]  Yezi Zhu,et al.  Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. , 2015, Cancer research.

[61]  Wei Li,et al.  Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer , 2015, The EMBO journal.

[62]  Bin Zhang,et al.  PhosphoSitePlus, 2014: mutations, PTMs and recalibrations , 2014, Nucleic Acids Res..

[63]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[64]  Susan S. Taylor,et al.  Kinases and Pseudokinases: Lessons from RAF , 2014, Molecular and Cellular Biology.

[65]  M. Rubin,et al.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.

[66]  Irena Nowak,et al.  Erk/MAP Kinase Signaling Pathway and Neuroendocrine Differentiation of Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[67]  M. Lemmon,et al.  Receptor tyrosine kinases with intracellular pseudokinase domains. , 2013, Biochemical Society transactions.

[68]  M. Gleave,et al.  A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[69]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[70]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[71]  Y. Minami,et al.  Ror family receptor tyrosine kinases regulate the maintenance of neural progenitor cells in the developing neocortex , 2012, Journal of Cell Science.

[72]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[73]  M. Greenberg,et al.  Wnt5a–Ror–Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis , 2012, Proceedings of the National Academy of Sciences.

[74]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[75]  P. Pujol,et al.  ROR2 Promoter Methylation Change in Osteoblastic Differentiation of Mesenchymal Stem Cells , 2011, Cell journal.

[76]  D. V. van Aalten,et al.  Pseudokinases-remnants of evolution or key allosteric regulators? , 2010, Current opinion in structural biology.

[77]  Y. Minami,et al.  Ror2/Frizzled Complex Mediates Wnt5a-Induced AP-1 Activation by Regulating Dishevelled Polymerization , 2010, Molecular and Cellular Biology.

[78]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[79]  N. Oue,et al.  Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase , 2010, Oncogene.

[80]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[81]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[83]  D. Gold,et al.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation , 2008, Nature Genetics.

[84]  H. Frierson,et al.  Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells. , 2007, Cancer research.

[85]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[86]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[87]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[88]  T. Hunter,et al.  The mouse kinome: discovery and comparative genomics of all mouse protein kinases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[89]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[90]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[91]  Jayoung Kim,et al.  Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. , 2002, Cancer research.

[92]  D. Robinson,et al.  The protein tyrosine kinase family of the human genome , 2000, Oncogene.

[93]  M. Dragunow,et al.  Is CREB a key to neuronal survival? , 2000, Trends in Neurosciences.

[94]  E. Perens,et al.  A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division , 1999, Nature.

[95]  D. Alessi,et al.  Mitogen‐ and stress‐activated protein kinase‐1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB , 1998, The EMBO journal.

[96]  P. Masiakowski,et al.  A novel family of cell surface receptors with tyrosine kinase-like domain. , 1992, The Journal of biological chemistry.

[97]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[98]  M. Montminy,et al.  Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133 , 1989, Cell.

[99]  M. Rubin,et al.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. , 2017, Cancer discovery.

[100]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[101]  Claude-Alain H. Roten,et al.  Fast and accurate short read alignment with Burrows–Wheeler transform , 2009, Bioinform..